Published in Oncol Rep on November 01, 2005
Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther (2010) 1.00
Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept. Proc Natl Acad Sci U S A (2009) 0.98
Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia (2008) 0.97
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer. Lung (2010) 0.80
Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy. Transl Oncol (2012) 0.77
Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies. PLoS One (2016) 0.75
Association between clusterin polymorphisms and esophageal squamous cell carcinoma risk in Han Chinese population. Int J Clin Exp Med (2015) 0.75
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A (2007) 4.04
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol (2007) 1.88
Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell (2004) 1.82
Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 1.82
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst (2013) 1.70
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res (2007) 1.67
MicroRNAs associated with metastatic prostate cancer. PLoS One (2011) 1.66
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res (2004) 1.66
Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol (2014) 1.61
Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res (2005) 1.55
TP53INP1 as new therapeutic target in castration-resistant prostate cancer. Prostate (2011) 1.51
Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res (2006) 1.49
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol (2007) 1.49
Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther (2007) 1.45
Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol (2012) 1.44
Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. World J Urol (2010) 1.43
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res (2008) 1.42
Applicability of blunt renal trauma classification of Japanese Association for the Surgery of Trauma (JAST). Int J Urol (2009) 1.41
Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature. Int J Urol (2011) 1.39
Conventional versus microdissection testicular sperm extraction for nonobstructive azoospermia. J Urol (2002) 1.36
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
Cluster-based network model for time-course gene expression data. Biostatistics (2006) 1.35
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol (2003) 1.31
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res (2008) 1.29
Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control (2005) 1.27
Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis (2013) 1.23
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.23
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res (2010) 1.22
Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. Can J Urol (2006) 1.21
Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol (2011) 1.18
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.18
Two cases of ganglioneuroma. Urology (2006) 1.16
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16
DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res (2007) 1.15
Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int (2006) 1.15
Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res (2013) 1.14
Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology (2002) 1.11
Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol (2008) 1.11
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res (2011) 1.11
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol (2006) 1.10
HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res (2012) 1.09
Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol (2012) 1.08
Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. FASEB J (2013) 1.06
Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol (2002) 1.05
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol (2005) 1.05
Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One (2012) 1.04
Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology (2008) 1.04
Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate (2004) 1.04
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J (2013) 1.04
Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res (2005) 1.03
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol (2009) 1.03
Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther (2005) 1.03
Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores. Urol Int (2007) 1.01
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res (2008) 1.01
The functioning antigens: beyond just as the immunological targets. Cancer Sci (2009) 1.01
A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther (2013) 1.01
Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol (2006) 1.00
Exiguobacterium oxidotolerans sp. nov., a novel alkaliphile exhibiting high catalase activity. Int J Syst Evol Microbiol (2004) 1.00
PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem (2009) 1.00
Differential expression and network inferences through functional data modeling. Biometrics (2008) 1.00
Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol (2006) 0.99
Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci (2014) 0.99
Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol Ther (2009) 0.98
Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol (2003) 0.98
Comparison of bifunctional chelates for (64)Cu antibody imaging. Eur J Nucl Med Mol Imaging (2010) 0.98
Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials (2009) 0.98
Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol (2009) 0.97
Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy. J Endourol (2008) 0.97
Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology (2008) 0.96
Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol (2002) 0.96
Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res (2007) 0.95
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther (2012) 0.95
Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nucl Med Biol (2008) 0.95
Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol (2004) 0.94
Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. FASEB J (2013) 0.94
Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab (2013) 0.94
Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int (2005) 0.94
Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. Clin Cancer Res (2003) 0.94
Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate (2010) 0.93